Literature DB >> 22275380

HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells.

Haojian Zhang1, Huawei Li, Hualin S Xi, Shaoguang Li.   

Abstract

Hypoxia-inducible factor-1α (HIF1α), a master transcriptional regulator of the cellular and systemic hypoxia response, is essential for the maintenance of self-renewal capacity of normal HSCs. It is still unknown whether HIF1α has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). Using a mouse model of CML, here we report that HIF1α plays a crucial role in survival maintenance of LSCs. Deletion of HIF1α impairs the propagation of CML through impairing cell-cycle progression and inducing apoptosis of LSCs. Deletion of HIF1α results in elevated expression of p16(Ink4a) and p19(Arf) in LSCs, and knockdown of p16(Ink4a) and p19(Arf) rescues the defective colony-forming ability of HIF1α(-/-) LSCs. Compared with normal HSCs, LSCs appear to be more dependent on the HIF1α pathway. Together, these results demonstrate that HIF1α represents a critical pathway in LSCs and inhibition of the HIF1α pathway provides a therapeutic strategy for eradicating LSCs in CML.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275380      PMCID: PMC3311277          DOI: 10.1182/blood-2011-10-387381

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

Authors:  Susan M Graham; Heather G Jørgensen; Elaine Allan; Charlie Pearson; Michael J Alcorn; Linda Richmond; Tessa L Holyoake
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  Telomerase activity in hematopoietic cells is associated with self-renewal potential.

Authors:  S J Morrison; K R Prowse; P Ho; I L Weissman
Journal:  Immunity       Date:  1996-09       Impact factor: 31.745

3.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.

Authors:  In-kyung Park; Dalong Qian; Mark Kiel; Michael W Becker; Michael Pihalja; Irving L Weissman; Sean J Morrison; Michael F Clarke
Journal:  Nature       Date:  2003-04-20       Impact factor: 49.962

4.  Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.

Authors:  Julie Lessard; Guy Sauvageau
Journal:  Nature       Date:  2003-04-20       Impact factor: 49.962

5.  Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice.

Authors:  Elena Almarza; José Carlos Segovia; Guillermo Guenechea; Susana G Gómez; Angel Ramírez; Juan Antonio Bueren
Journal:  Exp Hematol       Date:  2004-04       Impact factor: 3.084

6.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Authors:  Yiguo Hu; Yuhua Liu; Shawn Pelletier; Elisabeth Buchdunger; Markus Warmuth; Doriano Fabbro; Michael Hallek; Richard A Van Etten; Shaoguang Li
Journal:  Nat Genet       Date:  2004-04-18       Impact factor: 38.330

7.  BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

Authors:  Matthias Mayerhofer; Peter Valent; Wolfgang R Sperr; James D Griffin; Christian Sillaber
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

Review 8.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 9.  The BCR-ABL story: bench to bedside and back.

Authors:  Stephane Wong; Owen N Witte
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

View more
  82 in total

Review 1.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 2.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

Authors:  Gregg L Semenza
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 3.  Roles of the hypoxia response system in hematopoietic and leukemic stem cells.

Authors:  Keiyo Takubo; Toshio Suda
Journal:  Int J Hematol       Date:  2012-04-27       Impact factor: 2.490

4.  Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy.

Authors:  Isabella Spinello; Maria Teresa Quaranta; Rosa Paolillo; Elvira Pelosi; Anna Maria Cerio; Ernestina Saulle; Francesco Lo Coco; Ugo Testa; Catherine Labbaye
Journal:  Haematologica       Date:  2015-06-04       Impact factor: 9.941

5.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

Review 6.  Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity.

Authors:  Jin Qian; Erinn B Rankin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 7.  Hypoxia regulates the hematopoietic stem cell niche.

Authors:  Takayuki Morikawa; Keiyo Takubo
Journal:  Pflugers Arch       Date:  2015-10-21       Impact factor: 3.657

Review 8.  Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.

Authors:  Haojian Zhang; Shaoguang Li
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

Review 9.  Minimal Residual Disease Eradication in CML: Does It Really Matter?

Authors:  Srinivas K Tantravahi; Raga S Guthula; Thomas O'Hare; Michael W Deininger
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

10.  GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2.

Authors:  Zhong-Fa Yang; Haojian Zhang; Leyuan Ma; Cong Peng; Yaoyu Chen; Junling Wang; Michael R Green; Shaoguang Li; Alan G Rosmarin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.